Cargando…

Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile

Despite being a conceptually appealing alternative to conventional antibiotics, a major challenge toward the successful implementation of antisense treatments for bacterial infections is the development of efficient oligonucleotide delivery systems. Cationic vesicles (bolasomes) composed of dequalin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hegarty, John P, Krzeminski, Jacek, Sharma, Arun K, Guzman-Villanueva, Diana, Weissig, Volkmar, Stewart, David B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975145/ https://www.ncbi.nlm.nih.gov/pubmed/27536102 http://dx.doi.org/10.2147/IJN.S109600

Ejemplares similares

Cationic Amphiphilic Bolaamphiphile-based Delivery of Antisense Oligonucleotides Provides a Potentially Microbiome Sparing Treatment for C. difficile
por: Sharma, Arun K., et al.
Publicado: (2018)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
por: Østergaard, Michael E, et al.
Publicado: (2020)

Effects of combinations of gapmer antisense oligonucleotides on the target reduction
por: Yanagidaira, Mitsugu, et al.
Publicado: (2023)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides
por: Yoshida, Tokuyuki, et al.
Publicado: (2022)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Evaluation of off‐target effects of gapmer antisense oligonucleotides using human cells
por: Yoshida, Tokuyuki, et al.
Publicado: (2019)

Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics
por: Nilsson, Jesper R., et al.
Publicado: (2021)

A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells
por: Castanotto, Daniela, et al.
Publicado: (2015)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

Solid-Phase Synthesis of Boranophosphate/Phosphorothioate/Phosphate Chimeric Oligonucleotides and Their Potential as Antisense Oligonucleotides
por: Takahashi, Yuhei, et al.
Publicado: (2021)

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
por: Koller, Erich, et al.
Publicado: (2011)

Controlled sulfur-based engineering confers mouldability to phosphorothioate antisense oligonucleotides
por: Genna, Vito, et al.
Publicado: (2023)

Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus
por: Okamoto, Shunsuke, et al.
Publicado: (2023)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties
por: Miroshnichenko, S. K., et al.
Publicado: (2019)

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
por: Kasuya, Takeshi, et al.
Publicado: (2016)

A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
por: Shimojo, Masahito, et al.
Publicado: (2019)

Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts
por: Shin, Minwook, et al.
Publicado: (2022)

Chitosan Nanocomplexes for the Delivery of ENaC Antisense Oligonucleotides to Airway Epithelial Cells
por: Kolonko, A. Katharina, et al.
Publicado: (2020)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

Acute hepatotoxicity of 2′ fluoro-modified 5–10–5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins
por: Shen, Wen, et al.
Publicado: (2018)

Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment
por: Arrico, Lorenzo, et al.
Publicado: (2022)

Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy
por: Marrosu, Elena, et al.
Publicado: (2017)

Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cells
por: Kupryushkin, Maxim S., et al.
Publicado: (2021)

Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
por: Wan, W. Brad, et al.
Publicado: (2014)

Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity
por: Liang, Xue-Hai, et al.
Publicado: (2016)

Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2017)

Accessible light-controlled knockdown of cell-free protein synthesis using phosphorothioate-caged antisense oligonucleotides
por: Hartmann, Denis, et al.
Publicado: (2023)

Electronic Structures of LNA Phosphorothioate Oligonucleotides
por: Bohr, Henrik G., et al.
Publicado: (2017)

Phosphorothioate modified oligonucleotide–protein interactions
por: Crooke, Stanley T, et al.
Publicado: (2020)

Biomedically Relevant Applications of Bolaamphiphiles and Bolaamphiphile-Containing Materials
por: Hughes, Jake R., et al.
Publicado: (2021)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
por: Miller, Colton M., et al.
Publicado: (2016)

Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
por: Wang, Shiyu, et al.
Publicado: (2018)

Therapy with 2′-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption
por: Janssen, Manoe J., et al.
Publicado: (2019)

Towards Zwitterionic Oligonucleotides with Improved Properties: the NAA/LNA‐Gapmer Approach
por: Wojtyniak, Melissa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_42colgq4r3juohhvvvhrf2eono